Perceptive Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Perceptive Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,600,000	Closed	-$35.7M	–	166
2014 Q4	$35.7M	Buy	1,600,000 +947,000	+145%	+$17.9M	3%	6
2014 Q3	$10.2M	Buy	+653,000	New	+$9.76M	1.04%	26
2013 Q4	–	Sell	-289,500	Closed	-$3.28M	–	128
2013 Q3	$3.28M	Buy	+289,500	New	+$3.98M	0.27%	50
2013 Q2	–	Hold	0	–	–	–	39

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Perceptive Advisors's NBIX Position: Q2 2026 in Review

Perceptive Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 65,050 shares — an estimated $8.57M sold.

Perceptive Advisors first reported a position in NBIX in Q2 2013 and held it in 52 quarters. The position peaked at $587M in Q3 2018. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Perceptive Advisors reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
Perceptive Advisors sold 65,050 Neurocrine Biosciences shares in Q2 2026, an estimated $8.57M.
Perceptive Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 52 quarters.
Perceptive Advisors's Neurocrine Biosciences position peaked at $587M in Q3 2018.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.